nab-Paclitaxel promotes elevated intratumoral gemcitabine levels.

Slides:

Advertisements

Similar presentations

AZD7762 abrogated the G2 checkpoint in a novel hollow fiber assay.

Advertisements

Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.

BV6 increases tumor burden in bone.

Suppressive effect of CD39+CD73+ melanoma cells on T-cell proliferation, and reversion of this effect via treatment with the CD39-blocking antibody, CD39.

DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.

nab-Paclitaxel targets the tumor epithelial cells.

The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.

CCL5 is critical for the activity of CAFs and miR-CAFs.

A role for galectin-3 in promoting lung colonization in ST6GalNAc2-silenced cells. A role for galectin-3 in promoting lung colonization in ST6GalNAc2-silenced.

Imipramine and promethazine induce the apoptotic cell death of SCLC cells through activation of caspase-3. Imipramine and promethazine induce the apoptotic.

Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK inhibitors. Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK.

The selective PI3K inhibitor A66 suppresses PIP3 accumulation, AKT phosphorylation at Thr308, and YAP/TAZ–regulated gene expression in PDAC cells. The.

Chloroquine (CQ) improves tumor cell kill when used in combination with vemurafenib and chemotherapy in BRAFV600E-mutant cells. Chloroquine (CQ) improves.

Anti-SEMA4D and anti–CTLA-4 treatment is synergistic and increases the frequency of tumor-specific TILs and secretion of proinflammatory cytokines, while.

Protection from 4T1 tumor rechallenge in treated mice.

Inhibition of lung cancer cell proliferation and viability by CYT387.

NAPRT expression correlates to sensitivity for NAMPT inhibitors and to methylation of the CpG island of the NAPRT promoter. NAPRT expression correlates.

Modulation of Hh signaling modifies doxorubicin incorporation in leukemia cells. Modulation of Hh signaling modifies doxorubicin incorporation in leukemia.

Adaptive NK cells resist immunosuppression in the tumor microenvironment. Adaptive NK cells resist immunosuppression in the tumor microenvironment. FACS-sorted.

Synergistic effect of CNP and doxorubicin (DOX) on thiol oxidation.

PTENP1 serves as a ceRNA in the regulation of tumor growth in RCC

PTENP1 sensitizes renal cancer cells to chemotherapy.

Effect of LY on phosphorylation of various MAP kinase substrates in HeLa cells in vitro. Effect of LY on phosphorylation of various MAP kinase.

Scatterplots of qMSP analysis of candidate genes promoters in the discovery screen cohort, which consisted of 24 OSCC samples and 12 normal oral cavity.

A549 cells internalize NHF-ATP and NHF-ATP colocalizes with HMWFD

A, scatterplots of qMSP analysis of candidate genes promoters in the prevalence screen cohort, which consisted of 55 HNSCC tumor tissue samples and 37.

ST6GalNAc2 expression enhances tumor cells interaction with the vasculature. ST6GalNAc2 expression enhances tumor cells interaction with the vasculature.

l-2HG is elevated in RCC tumors and cell lines.

Vascular staining in CWR22R xenograft tumors.

VEGF expression in neoplastic and normal prostate tissue.

Angiogenesis in tumors formed by cells varying in the expression of CXCR2. Angiogenesis in tumors formed by cells varying in the expression of CXCR2. A,

N-3 PUFAs promote endometrial cancer cell apoptosis in vitro and in vivo. n-3 PUFAs promote endometrial cancer cell apoptosis in vitro and in vivo. HEC-1-A.

Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.

IL8 and TNFα are required for neutrophil-induced UMSCC47 increase in invasion. IL8 and TNFα are required for neutrophil-induced UMSCC47 increase in invasion.

Irradiated whole-cell vaccination with MOC1, but not MOC2, induces immunologic memory. Irradiated whole-cell vaccination with MOC1, but not MOC2, induces.

Pharmacodynamic evaluation of VT-464 and ABI in MR49F xenograft model.

Fig. 1 WNT antagonists synergize with taxanes.

Characterization of DNA-PK and PARP-1 levels and activities in the cell lines studied. Characterization of DNA-PK and PARP-1 levels and activities in the.

Prostaglandin E2 attenuates the host antitumor immunity to promote the HFD-induced HCC development. Prostaglandin E2 attenuates the host antitumor immunity.

Deletion of Tgfbr2 in myeloid cells elevated IFN-γ production in CD8+ T cells, and systemic IFN-γ neutralization diminished metastasis inhibition in Tgfbr2MyeKO.

A and B, intratumoral DC-AdCCL21 leads to reduction in growth rates of bilateral tumors. A and B, intratumoral DC-AdCCL21 leads to reduction in growth.

Pdcd4 expression inhibits AP-1 transactivation.

TBK1 signaling also promotes basal autophagy in 8988T cells.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

Three different endocytoses contribute to ATP internalization.

Adhesion of T-cell clones to autologous tumor cells under shear stress

Wnt5A decreases ROR1 expression through proteasomal degradation.

Nab-Paclitaxel (nP) slows tumor growth, improves survival, and decreases metastasis. nab-Paclitaxel (nP) slows tumor growth, improves survival, and decreases.

RhuαVEGF and rhuαVEGF/paclitaxel mediated growth inhibition in an androgen-independent prostate cancer xenograft model. rhuαVEGF and rhuαVEGF/paclitaxel.

Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells. Combination of R848 and anti-CD200R affects activation of tumor-infiltrating.

AKT activation in HCC2429 is SRC- but not Notch-dependent.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

BEZ235 induces accelerated senescence after radiation (IR) in vitro.

ADU-S100 primes the innate immune system in tolerant, tumor bearing neu/N mice. ADU-S100 primes the innate immune system in tolerant, tumor bearing neu/N.

Intratumoral injections of small doses of agonist anti-CD137 mAb to directly act on CD137+ TILs render systemic immunotherapeutic effects that are synergistic.

Enrichment of two rare SNPs among ABC DLBCL tumors.

IL35 regulation of tumor growth is accompanied by suppression of CD4+ effector T-cell activity and expansion of Tregs. IL35 regulation of tumor growth.

Cabozantinib causes significant tumor cell elimination in vivo, but modest apoptosis induction in vitro. Cabozantinib causes significant tumor cell elimination.

Increased tumorigenic activities of TIM-3–expressing RCC cells.

Transgenic mice with constitutively active NIK show increased tumor growth in bone. Transgenic mice with constitutively active NIK show increased tumor.

Ceritinib is a potent ALK inhibitor in crizotinib-naïve models.

Increased invasion does not require direct contact between neutrophils and UMSCC47. Increased invasion does not require direct contact between neutrophils.

In vivo effect of KIN-193 on PTEN-deficient tumors.

Cell counts of immune infiltrate and expression of galectin-1 and galectin-3 in the short-, medium-, and long-term survival cohorts. Cell counts of immune.

TAMs upregulate DNMT1 in gastric cancer cells through the CCL5/CCR5/STAT3 pathway. TAMs upregulate DNMT1 in gastric cancer cells through the CCL5/CCR5/STAT3.

Antiangiogenic effects of PI3K inhibitor NVP-BKM120.

MET activation confers resistance to cetuximab (Cmab) or panitumumab (Pmab) in colon cancer cell lines in vitro and in vivo. MET activation confers resistance.

Wnt5A and ROR2 contribute to intrinsic resistance to BRAF inhibitors.

WEE1 inhibition followed by TRAIL treatment results in apoptotic cell death in MB231 cells. WEE1 inhibition followed by TRAIL treatment results in apoptotic.

DHA and dietary n-3 PUFAs inhibit endometrial cancer cell growth in vitro and in xenograft models. DHA and dietary n-3 PUFAs inhibit endometrial cancer.

Presentation transcript:

nab-Paclitaxel promotes elevated intratumoral gemcitabine levels. nab-Paclitaxel promotes elevated intratumoral gemcitabine levels. A, 2′,2′-difluorodeoxcytidine:2′,2′-difluorodeoxyuridine (dfdC:dFdU) ratio in bulk tumor was quantified in mice 2 hours after the last dose of gemcitabine. (n ≥ 12). B, intratumoral levels of dFdCTP were measured in duplicate samples from mice in each cohort 2 hours after the last dose of gemcitabine. (n ≥ 12) C, intratumoral levels of paclitaxel were measured in samples from mice in each cohort 4 hours after the last dose of nab-paclitaxel (n ≥ 7). D, 2 KPC cell lines were pretreated with 10 μmol/L paclitaxel or dimethyl sulfoxide for 36 hours or 10 μmol/L tetrahydrouridine (THU; cytidine deaminase inhibitor) for 30 minutes as a positive control and incubated with 1 μmol/L gemcitabine for 2 hours. Levels of dFdCTP were then measured. Data are representative of 3 independent experiments. G, gemcitabine; nP + G, nab-paclitaxel and gemcitabine. Kristopher K. Frese et al. Cancer Discovery 2012;2:260-269 ©2012 by American Association for Cancer Research